secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evoke Pharma Inc (—)
CIK:        0001403708
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0000950170-24-059477
Event type: other_material
Sentiment:  negative
Materiality: 0.55
Item codes: 4.02
LLM model:  deepseek-v4-flash:cloud@v2

Evoke Pharma restates FY 2023 and interim 2023 financials over note classification error
--------------------------------------------------------------------------------

- Audit Committee determined prior financials for FY2023, Q2 and Q3 2023 are non-reliable due to classification error.
- Note payable to Eversana misclassified as long-term instead of current; net profit trigger allowed termination.
- Error had no impact on total assets, liabilities, equity, or operations; only balance sheet classification.
- Material weakness in internal control over financial reporting identified; remediation plan to be filed.
- Restated financial statements for affected periods expected on Form 10-K/A as soon as practicable.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1403708/000095017024059477/0000950170-24-059477-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1403708/000095017024059477/evok-20240513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-059477

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer